GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Shiller PE Ratio

Lexaria Bioscience (Lexaria Bioscience) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lexaria Bioscience Shiller PE Ratio Historical Data

The historical data trend for Lexaria Bioscience's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Shiller PE Ratio Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexaria Bioscience Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexaria Bioscience's Shiller PE Ratio

For the Biotechnology subindustry, Lexaria Bioscience's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Shiller PE Ratio falls into.



Lexaria Bioscience Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lexaria Bioscience's E10 for the quarter that ended in Feb. 2024 is calculated as:

For example, Lexaria Bioscience's adjusted earnings per share data for the three months ended in Feb. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.06/125.4675*125.4675
=-0.060

Current CPI (Feb. 2024) = 125.4675.

Lexaria Bioscience Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -0.545 98.920 -0.691
201407 -0.545 99.315 -0.689
201411 -0.273 99.078 -0.346
201502 -0.273 99.078 -0.346
201505 -0.273 100.263 -0.342
201508 -0.109 100.579 -0.136
201511 -0.300 100.421 -0.375
201602 -0.300 100.421 -0.375
201605 -0.300 101.765 -0.370
201608 -0.300 101.686 -0.370
201611 -0.300 101.607 -0.370
201702 -0.300 102.476 -0.367
201705 -0.300 103.108 -0.365
201708 -0.300 103.108 -0.365
201711 -0.300 103.740 -0.363
201802 -0.600 104.688 -0.719
201805 -1.500 105.399 -1.786
201808 -0.300 106.031 -0.355
201811 -0.300 105.478 -0.357
201902 -0.300 106.268 -0.354
201905 -0.300 107.927 -0.349
201908 -0.300 108.085 -0.348
201911 -0.330 107.769 -0.384
202002 -0.380 108.559 -0.439
202005 -0.500 107.532 -0.583
202008 -0.240 108.243 -0.278
202011 -0.240 108.796 -0.277
202102 0.090 109.745 0.103
202105 -0.500 111.404 -0.563
202108 -0.240 112.668 -0.267
202111 -0.350 113.932 -0.385
202202 -0.250 115.986 -0.270
202205 -0.410 120.016 -0.429
202208 -0.240 120.569 -0.250
202211 -0.300 121.675 -0.309
202302 -0.220 122.070 -0.226
202305 -0.370 124.045 -0.374
202308 -0.120 125.389 -0.120
202311 -0.130 125.468 -0.130
202402 -0.060 125.468 -0.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lexaria Bioscience  (NAS:LEXX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lexaria Bioscience Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience (Lexaria Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Executives
Catherine C. Turkel director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey officer: Chief Financial Officer 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka director, 10 percent owner, officer: CEO 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle officer: Secretary 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr director
Brian W. Quigley director 100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie director 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger officer: CFO 8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty director, 10 percent owner 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar director, officer: CFO 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter director 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford director 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke officer: Sr. VP, Business Development 38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini director, 10 percent owner 11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan director, officer: Vice President - Corp Develop SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6